+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Short Bowel Syndrome Market by Drug Class (GLP-2, Glutamine, Growth Hormone), Distribution Channel (Hospital Pharmacies, Online Sales, Retail Pharmacies) - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4985952
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Short Bowel Syndrome Market size was estimated at USD 818.23 million in 2023, USD 966.42 million in 2024, and is expected to grow at a CAGR of 19.14% to reach USD 2,788.72 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Short Bowel Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Short Bowel Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Short Bowel Syndrome Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc., AstraZeneca PLC, Emmaus Life Sciences, Inc., Merck KGaA, Nestlé S.A., Novartis International AG, OPKO Health, Inc., Oxthera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio and Company, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., VectivBio AG, Viatris Inc., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Short Bowel Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • GLP-2
    • Glutamine
    • Growth Hormone
  • Distribution Channel
    • Hospital Pharmacies
    • Online Sales
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Short Bowel Syndrome Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Short Bowel Syndrome Market?
  3. What are the technology trends and regulatory frameworks in the Short Bowel Syndrome Market?
  4. What is the market share of the leading vendors in the Short Bowel Syndrome Market?
  5. Which modes and strategic moves are suitable for entering the Short Bowel Syndrome Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Short Bowel Syndrome Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased Prevalence of Short Bowel Syndrome and Awareness Programs
5.1.1.2. Rising Efforts in the Launch of Effective Treatments
5.1.2. Restraints
5.1.2.1. Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
5.1.3. Opportunities
5.1.3.1. Development of Short Bowel Syndrome Drugs is at a Nascent Stage
5.1.3.2. Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
5.1.4. Challenges
5.1.4.1. Limited Initial Diagnostic and Availability of Advanced Option
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Short Bowel Syndrome Market, by Drug Class
6.1. Introduction
6.2. GLP-2
6.3. Glutamine
6.4. Growth Hormone
7. Short Bowel Syndrome Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Sales
7.4. Retail Pharmacies
8. Americas Short Bowel Syndrome Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Short Bowel Syndrome Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Short Bowel Syndrome Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. 9 Meters Biopharma, Inc.
12.1.2. Adocia SAS
12.1.3. Ardelyx Inc.
12.1.4. AstraZeneca PLC
12.1.5. Emmaus Life Sciences, Inc.
12.1.6. Merck KGaA
12.1.7. Nestlé S.A.
12.1.8. Novartis International AG
12.1.9. OPKO Health, Inc.
12.1.10. Oxthera AB
12.1.11. Pfizer Inc.
12.1.12. PhaseBio Pharmaceuticals Inc.
12.1.13. Sancilio and Company, Inc.
12.1.14. Swedish Orphan Biovitrum AB
12.1.15. Takeda Pharmaceutical Company Limited
12.1.16. Teva Pharmaceutical Industries Ltd.
12.1.17. VectivBio AG
12.1.18. Viatris Inc.
12.1.19. Zealand Pharma A/S
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. SHORT BOWEL SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SHORT BOWEL SYNDROME MARKET DYNAMICS
FIGURE 7. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 10. SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SHORT BOWEL SYNDROME MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SHORT BOWEL SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 20. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 33. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 57. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 100. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
TABLE 101. SHORT BOWEL SYNDROME MARKET LICENSE & PRICING

Companies Mentioned

  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc.
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Merck KGaA
  • Nestlé S.A.
  • Novartis International AG
  • OPKO Health, Inc.
  • Oxthera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio and Company, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VectivBio AG
  • Viatris Inc.
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Table Information